{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:48:04Z","timestamp":1790837284635,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,18]]},"DOI":"10.7759\/cureus.32665","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T18:22:24Z","timestamp":1671387744000},"source":"Crossref","is-referenced-by-count":2,"title":["A Systematic Review of CD34+ Stem Cell Therapy as an Innovative and Efficient Treatment for the Management of Refractory Angina"],"prefix":"10.7759","author":[{"given":"Vruti","family":"Vithani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bansi","family":"Sutariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paghunda","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawia N","family":"Aburumman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani Ishwarya","family":"Muthanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi Radhakrishnan","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sri","family":"Penumetcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx764","article-title":"Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials","volume":"39","author":"Henry TD","year":"2018","unstructured":"Henry TD, Losordo DW, Traverse JH, et al.. Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J. 2018, 39:2208-16. 10.1093\/eurheartj\/ehx764","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0046","article-title":"CD34(+) cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina","volume":"9","author":"Johnson GL","year":"2020","unstructured":"Johnson GL, Henry TD, Povsic TJ, et al.. CD34(+) cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina. Stem Cells Transl Med. 2020, 9:1147-52. 10.1002\/sctm.20-0046","journal-title":"Stem Cells Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2018.05.018","article-title":"Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials","volume":"20","author":"Velagapudi P","year":"2019","unstructured":"Velagapudi P, Turagam M, Kolte D, et al.. Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials. Cardiovasc Revasc Med. 2019, 20:215-9. 10.1016\/j.carrev.2018.05.018","journal-title":"Cardiovasc Revasc Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319644","article-title":"IMPROvE-CED trial: Intracoronary autologous CD34+ cell therapy for treatment of coronary endothelial dysfunction in patients with angina and nonobstructive coronary arteries","volume":"130","author":"Corban MT","year":"2022","unstructured":"Corban MT, Toya T, Albers D, et al.. IMPROvE-CED trial: Intracoronary autologous CD34+ cell therapy for treatment of coronary endothelial dysfunction in patients with angina and nonobstructive coronary arteries. Circ Res. 2022, 130:326-38. 10.1161\/CIRCRESAHA.121.319644","journal-title":"Circ Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051137","article-title":"Angiogenic CD34 stem cell therapy in coronary microvascular repair: A systematic review","volume":"10","author":"Rai B","year":"2021","unstructured":"Rai B, Shukla J, Henry TD, Quesada O. Angiogenic CD34 stem cell therapy in coronary microvascular repair: A systematic review. Cells. 2021, 10:10.3390\/cells10051137","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v11.i5.138","article-title":"Transplantation of CD34+ cells for myocardial ischemia","volume":"11","author":"Matta A","year":"2021","unstructured":"Matta A, Nader V, Galinier M, Roncalli J. Transplantation of CD34+ cells for myocardial ischemia. World J Transplant. 2021, 11:138-46. 10.5500\/wjt.v11.i5.138","journal-title":"World J Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0240","article-title":"Autologous CD34+ Cell Therapy for Ischemic Tissue Repair","volume":"83","author":"Sietsema WK","year":"2019","unstructured":"Sietsema WK, Kawamoto A, Takagi H, Losordo DW. Autologous CD34+ Cell Therapy for Ischemic Tissue Repair. Circ J. 2019, 83:1422-30. 10.1253\/circj.CJ-19-0240","journal-title":"Circ J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.687376","article-title":"Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial","volume":"115","author":"Losordo DW","year":"2007","unstructured":"Losordo DW, Schatz RA, White CJ, et al.. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial. Circulation. 2007, 115:3165-72. 10.1161\/CIRCULATIONAHA.106.687376","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3727\/096368916X691484","article-title":"Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study","volume":"25","author":"Henry TD","year":"2016","unstructured":"Henry TD, Schaer GL, Traverse JH, et al.. Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study. Cell Transplant. 2016, 25:1701-11. 10.3727\/096368916X691484","journal-title":"Cell Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.05.003","article-title":"The RENEW trial: Efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina","volume":"9","author":"Povsic TJ","year":"2016","unstructured":"Povsic TJ, Henry TD, Traverse JH, et al.. The RENEW trial: Efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina. JACC Cardiovasc Interv. 2016, 9:1576-85. 10.1016\/j.jcin.2016.05.003","journal-title":"JACC Cardiovasc Interv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.010802","article-title":"Autologous CD34+ stem cell therapy increases coronary flow reserve and reduces angina in patients with coronary microvascular dysfunction","volume":"15","author":"Henry TD","year":"2022","unstructured":"Henry TD, Bairey Merz CN, Wei J, et al.. Autologous CD34+ stem cell therapy increases coronary flow reserve and reduces angina in patients with coronary microvascular dysfunction. Circ Cardiovasc Interv. 2022, 15:e010802. 10.1161\/CIRCINTERVENTIONS.121.010802","journal-title":"Circ Cardiovasc Interv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa027","article-title":"Promise of autologous CD34+ stem\/progenitor cell therapy for treatment of cardiovascular disease","volume":"116","author":"Prasad M","year":"2020","unstructured":"Prasad M, Corban MT, Henry TD, Dietz AB, Lerman LO, Lerman A. Promise of autologous CD34+ stem\/progenitor cell therapy for treatment of cardiovascular disease. Cardiovasc Res. 2020, 116:1424-33. 10.1093\/cvr\/cvaa027","journal-title":"Cardiovasc Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2012.12.003","article-title":"Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials","volume":"29","author":"Li N","year":"2013","unstructured":"Li N, Yang YJ, Zhang Q, Jin C, Wang H, Qian HY. Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials. Can J Cardiol. 2013, 29:908-14. 10.1016\/j.cjca.2012.12.003","journal-title":"Can J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050459","article-title":"Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization","volume":"203","author":"Qin G","year":"2006","unstructured":"Qin G, Ii M, Silver M, et al.. Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med. 2006, 203:153-63. 10.1084\/jem.20050459","journal-title":"J Exp Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036202","article-title":"The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration","volume":"110","author":"Grote K","year":"2007","unstructured":"Grote K, Salguero G, Ballmaier M, Dangers M, Drexler H, Schieffer B. The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. Blood. 2007, 110:877-85. 10.1182\/blood-2006-07-036202","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.01.018","article-title":"Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke","volume":"263","author":"Tsuji M","year":"2014","unstructured":"Tsuji M, Taguchi A, Ohshima M, et al.. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience. 2014, 263:148-58. 10.1016\/j.neuroscience.2014.01.018","journal-title":"Neuroscience"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/86498","article-title":"Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function","volume":"7","author":"Kocher AA","year":"2001","unstructured":"Kocher AA, Schuster MD, Szabolcs MJ, et al.. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001, 7:430-6. 10.1038\/86498","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2004-0200","article-title":"Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model","volume":"23","author":"Yoshioka T","year":"2005","unstructured":"Yoshioka T, Ageyama N, Shibata H, et al.. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. Stem Cells. 2005, 23:355-64. 10.1634\/stemcells.2004-0200","journal-title":"Stem Cells"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo DW","year":"2011","unstructured":"Losordo DW, Henry TD, Davidson C, et al.. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011, 109:428-36. 10.1161\/CIRCRESAHA.111.245993","journal-title":"Circ Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/114416-a-systematic-review-of-cd34-stem-cell-therapy-as-an-innovative-and-efficient-treatment-for-the-management-of-refractory-angina","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:11Z","timestamp":1707507971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/114416-a-systematic-review-of-cd34-stem-cell-therapy-as-an-innovative-and-efficient-treatment-for-the-management-of-refractory-angina"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,18]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.32665","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,18]]}}}